Navigation Links
Impact2 12-Channel Electronic Pipettor, 0.5-12.5L

ProductsImpact2 12-Channel Electronic Pipettor, 0.5-12.5L
Company Matrix Technologies Corporation
Item Impact2 12-Channel Electronic Pipettor, 0.5-12.5L
Features 
Description Ergonomic Design for Unparalleled Comfort
Pick one of our pipettors up and use it. Notice the balance. Notice the trigger and ejector positionsright where they should beeven if youre left-handed. Thats because our pipettors are ergonomically designed to help avoid repetitive stress injuries caused by long hours of pipetting.

Productivity In The Palm Of Your Hand
Start dispensing right away or create a program with up to 40 steps. Perform neat sample additions, simple dilutions, serial dilutions, rapid reagent additions, supernatant collections or other procedures individually or programmed in sequence according to protocol. Turn the pipettor off and it automatically remembers your most recent sequence the next time you turn it on.

Simple Calibration
In-lab calibration can be performed quickly and easily.The software provides a trail of calibration information.

Speed Control
Impact and Impact2 pipettors allow convenient on-the-fly speed control. Aspiration and dispense speeds may be individually selected from three (Impact) or five (Impact2) different settings. Impact2 features two additional slower speeds for dispensing onto electrophoresis gels.

Rechargeable, Long-Lasting Batteries
Our multichannel pipettors come with a power supply adapter and one set of NiCad batteries rated for 1200 cycles before recharging. (16-channel pipettors are provided with lithium ion batteriessee Accessories for details.) You have the option of continuing to use the pipettor while its rechargingjust plug it into the power supply and continue operation. The battery compartment is on the underside of the control panel for convenient replacement.

Info Matrix Technologies Corporation
Customer Service: (866) 229-9770
Web site: http://www.matrixtechcorp.com/index.aspx

Related medicine products :

1. Impact2 Single Channel Pipettor, 5-250L
2. Impact2 Shorty, 5-250L
3. Impact2 16-Channel Electronic Pipettor, 1.0-30L
4. Impact2 16-Channel Electronic Pipettor, 2-125L
5. Impact2 16-Channel Electronic Pipettor, 0.5-12.5L
6. Impact2 12-Channel Electronic Pipettor, 2-125L
7. Impact2 12-Channel Electronic Pipettor, 5-250L
8. Impact2 12-Channel Electronic Pipettor, 15-850L
9. Impact2 8-Channel Electronic Pipettor, 2-125L
10. Impact2 8-Channel Electronic Pipettor, 5-250L
11. Impact2 8-Channel Electronic Pipettor, 15-1250L
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn
...he ProTime Microcoagulation System monitors warfar...ient self-testing. Enhancements include an easy-t...le and replaceable battery. Software updates incl... computer or be transmitted to a LIS or EMR databa...
...ince 1994 the CoaguChek System has been providing ...eeded most, at the point of care. , The CoaguChe... of patients self-testing when monitoring on Couma...m allows the user to obtain a result from a finger...
...he Instacup Multi-Drug Screen Panel is used for th...man urine. The Instacup Panel consists of a test c... test card is inserted and the sample sealed with ...ot necessary to remove the test card to read the r...
Medicine Products:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...nd to prevent heart attacks, but the little white ... A new study says aspirin and related painkillers ...ed to potentially deadly infections in people with...e presence of the microbe, called human cytomegalo...
...tion approved to treat both major strains of influ...able for the start of this flu season because prod...cation, Tamiflu Oral Suspension product, was suppo... informed the FDA of its production problems, but ...
...rewarning from severe periodontal disease than non...the Journal of periodontology.// Researchers from ...edicine compared 13 type 1 diabetic and 20 non-dia...pregnancy to examine the effects of periodontal in...
...the Hopkins Heart Institute, a blunt and apparentl...iac death. When it comes to accidents and sports i...le fear. According to researchers, at the a blow t...s. The researchers looked at 100 cases of a rare ...
Other Medicine News:
(Date:10/6/2008)... More than 60 percent of moderate to severe pati... percent achieved endoscopic remission at Week 10,...at the American College,of Gastroenterology (ACG) .../- UCB today presented data from a,la...provement in Crohn,s,disease (CD) with a biologic ...
(Date:10/6/2008)... Improved Pharmacokinetic Characteristics of Naltr...erability in Clinical Trials -, PHOENIX, Oct. 6 /...c.,(Nasdaq: OREX ), a biopharmaceutical company f...al nervous system-related disorders, today present...(R) (naltrexone SR /,bupropion SR), successfully a...
(Date:10/6/2008)... SEATTLE, Oct. 6 /- Dendr...nce call today, Monday, October 6, 2008 at 9:00 AM...rim analysis of its IMPACT,(IMmunotherapy for Pros...B),clinical trial of PROVENGE(R) (sipuleucel-T), t...otherapy for the treatment of advanced prostate,ca...
(Date:10/6/2008)... Recent study revealed that drinking polyphenol-...ith changes in appetite, energy intake or body,wei...ar consumption of 100%,polyphenol-rich Concord gra...s not associated with changes in appetite and was ...ew data presented at the 49th Annual Meeting of,th...
Breaking Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3New Source of Heart Stem Cells Found 22491 1New Source of Heart Stem Cells Found 22491 2RxPop com Wins 7th Annual Horizon Interactive Award 22487 1RxPop com Wins 7th Annual Horizon Interactive Award 22487 2Health and Beauty Come Full Circle 3A Chado En Brings Full Benefit of Japanese Green Tea to Spas 22483 1Health and Beauty Come Full Circle 3A Chado En Brings Full Benefit of Japanese Green Tea to Spas 22483 2Concuity Announces Partnership with Financial Healthcare Systems LLC 6148 1Concuity Announces Partnership with Financial Healthcare Systems LLC 6148 2Concuity Announces Partnership with Financial Healthcare Systems LLC 6148 3Concuity Announces Partnership with Financial Healthcare Systems LLC 6148 4
....J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQ...opharmaceutical company focused on acquiring, deve...ds, announced data from its,preclinical studies of...r the treatment of solid and hematologic tumors.,P...April 2007,Annual Meeting of the American Associat...
...sitive Top-Line Phase III Results for,Keppra® ...n,Paediatric Patients from One Month to Less than ...2007 - UCB today announced,positive top-line resul...ti-centre, placebo-controlled study evaluating the...acetam) (20-50,mg/kg/day) as adjunctive therapy in...
Other Medicine Technology:VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5